Total
0
Shares
MGC Pharmaceuticals (ASX:MXC) - Co Founder and Managing Director, Roby Zomer - The Market Herald
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MGC Pharmaceuticals (MXC) has received a significantly increased order from Swiss PharmaCan (SPC) for its ArtemiC Rescue product line
  • The companies first entered an agreement last month with Swiss PharmaCan initially receiving 40,000 units per quarter over a three year period
  • MGC Pharma today announced an 85 per cent increase to the initial purchase order, bringing the new total order to more than $425,000
  • ArtemiC is MGC's natural, immune-modulation formula that is made up of Vitamin C and herbal extracts used to treat anti-inflammatory illnesses
  • A phase II trial from December showed that the product reduces the symptoms and pain associated with COVID-19
  • MGC Pharma is up 2.5 per cent, trading at 8.2 cents

MGC Pharmaceuticals (MXC) has received a significantly increased order from Swiss PharmaCan (SPC) for its ArtemiC Rescue product line.

The companies first entered an agreement last month with Swiss PharmaCan initially receiving 40,000 units per quarter over a three-year period.

It will then be distributed as a food supplement worldwide with the exception of a few select countries.

SPC will be responsible for the acquisition of relevant permits, approvals, licences and certificates, as well as marketing, promotion, advertising and import.

MGC Pharma today announced an 85 per cent increase to the initial purchase order received in February, bringing the new initial total order to more than $425,000.

ArtemiC is made up of Artemisinin, a drug from a fern-like plant that is used against malaria, and Curcumin, a chemical that aids in anti-inflammatory and antioxidants.

It is then mixed with Vitamin C and Boswellia serrata, a herbal extract used to treat inflammatory illnesses.

Following a phase two double-blind, placebo-controlled clinical trial on COVID-19 patients, ArtemiC was shown to reduce the symptoms and pain associated with COVID-19.

Further, the product was shown to be safe and effective for human use.

"We are pleased to have extended our agreement with Swiss PharmaCan AG for ArtemiC Rescue," Co-Founder and Managing Director Roby Zomer said.

"This further agreement will provide more people access to the natural therapeutic benefits of the supplement and ease suffering following the successful phase two trial results in December," he added.

MGC Pharma is up 2.5 per cent on the market, trading at 8.2 cents at 11:27 am AEDT.

MXC by the numbers
More From The Market Herald
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" TGA fast tracks evaluation of Telix Pharmaceuticals’ (ASX:TLX) cancer imaging product

The Theraputic Goods Administration (TGA) has commenced a priority evaluation process for Telix Pharmaceuticals’ (TLX) prostate cancer imaging product, Illuccix.
Pharmaxis (ASX:PXS) - CEO, Gary Phillips (left) - The Market Herald

" Pharmaxis (ASX:PXS) to raise $4.4M via placement

Pharmaxis (PXS) has received firm commitments to raise $4.4 million through a placement.
Universal Biosensors (ASX:UBI) - CEO, John Sharman - The Market Herald

" Universal Biosensors (ASX:UBI) toasts new distribution agreement for wine testing device

Universal Biosensors (UBI) has entered into a non-exclusive agreement with Singularity SpA to distribute its wine testing platform device in Chile.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" Paradigm Biopharmaceuticals (ASX:PAR) enrols first participant in osteoarthritis trial

Paradigm Biopharmaceuticals (PAR) has enrolled its first patient in its knee osteoarthritis (OA) biomarker study in Box Hill, Victoria.